For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

GLP-1 / Metabolic

Survodutide

Also known as: BI 456906

Survodutide is a dual GLP-1 / glucagon receptor agonist co-developed by Boehringer Ingelheim and Zealand Pharma. NOT FDA-approved; received FDA Breakthrough Therapy Designation in 2024 for non-cirrhotic MASH with moderate/advanced fibrosis. Phase 3 ongoing (SYNCHRONIZE in obesity/T2DM; LIVERAGE and LIVERAGE-Cirrhosis in MASH).

Real-time market data

Pricing for Survodutide

Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.

Average price

$13.55/mg

range $7.80–$32.10/mg

Sellers

21

from $0.00

45-day trend

-29.3%

vs 45-day avg $/mg

16 of 21 sellers have a current price· 8 stale listings hidden (not seen in 7 days)

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Independent evidence

COAs for Survodutide

23 third-party tests across 5 vendors. Each card links to the full report.

All 23 COAs for Survodutide →
Measured purity 99.4%–99.9% across 14 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.93 %
May 2026
Freedom Diagnostics Moderate

For

Survodutide

by Profound Aminos· batch Yellow Cap

Aggregated · 3rd-party listing
99.82 %
May 2026
Freedom Diagnostics Moderate

For

Survodutide

by Real Peptides· batch Clear Cap/Purple Crimp

Aggregated · 3rd-party listing
99.70 %
Jan 2026
Vanguard Laboratory Strong

For

Suvrodutide

by Kimera Chems· batch KC-SVD-BLK1

Aggregated · 3rd-party listing
99.76 %
Dec 2025
Janoshik Analytical Limited · HPLC

For

Survodutide

by Skye Peptides· batch SV25-12-001

✓ Vendor-published
99.88 %
Nov 2025
Janoshik Analytical Limited

For

Survodutide

by Ruo Bio· batch sur001

COA on file
Aggregated · 3rd-party listing
99.48 %
Nov 2025
Freedom Diagnostics Moderate

For

Survodutide

by Kimera Chems· batch KC-SVD-RED1

Aggregated · 3rd-party listing
99.78 %
Oct 2025
Janoshik Analytical Limited · HPLC

For

Survodutide

by Skye Peptides· batch SV25-06-001

Aggregated · 3rd-party listing
99.44 %
Sep 2025
Janoshik Analytical Limited

For

Survodutide

by EZ Peptides· batch EZP-SURV1009082025-01

✓ Vendor-published
99.47 %
Sep 2025
Janoshik Analytical Limited

For

Survodutide

by EZ Peptides· batch EZP-SURV1009082025-01

COA on file
Aggregated · 3rd-party listing
99.78 %
Jan 2025
MZ Biolabs Moderate · HPLC

For

Survodutide

by Profound Aminos· batch 2025-01-23

Aggregated · 3rd-party listing
99.85 %
Sep 2024
MZ Biolabs Moderate · HPLC

For

Survodutide

by Hydro Research Peptides· batch 2024-08-05

Aggregated · 3rd-party listing
99.85 %
Sep 2024
MZ Biolabs Moderate

For

Survodutide

by Optima Supply· batch 2024-08-05

Aggregated · 3rd-party listing
99.47 %
Aug 2024
Janoshik Analytical Limited · HPLC

For

Survodutide

by Hydro Research Peptides· batch Survodutide-6028

Aggregated · 3rd-party listing
99.47 %
Aug 2024
Janoshik Analytical Limited

For

Survodutide

by Optima Supply· batch Survodutide-6033

Aggregated · 3rd-party listing
99.80 %
Vanguard Laboratory Strong

For

Survodutide

by Peptidology· batch 1671

Aggregated · 3rd-party listing
99.10 %
Vanguard Laboratory Strong

For

Suvrodutide

by Kimera Chems· batch KC-SVD-RED1

Aggregated · 3rd-party listing
Dec 2025

Purity not on file

Janoshik Analytical Limited

For

Survodutide

by Skye Peptides· batch SV25-12-001

Aggregated · 3rd-party listing
Dec 2025

Purity not on file

Janoshik Analytical Limited

For

Survodutide

by Skye Peptides· batch SV25-12-001

Aggregated · 3rd-party listing
Oct 2025

Purity not on file

Janoshik Analytical Limited

For

Survodutide

by Skye Peptides· batch SV25-06-001

Aggregated · 3rd-party listing
Oct 2025

Purity not on file

Janoshik Analytical Limited

For

Survodutide

by Skye Peptides· batch SV25-06-001

Aggregated · 3rd-party listing
Aug 2024

Purity not on file

Janoshik Analytical Limited

For

Survodutide

by Hydro Research Peptides· batch Survodutide-6028

Aggregated · 3rd-party listing
Aug 2024

Purity not on file

Janoshik Analytical Limited

For

Survodutide

by Hydro Research Peptides· batch Survodutide-6028

✓ Vendor-published

Purity not on file

Lab unknown

For

Survodutide

by Ruo Bio

COA on file
Research depth

20 citations indexed for Survodutide

All research on Survodutide →

Study · 2026

Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity

Aims This post hoc analysis evaluated the effect of survodutide on beta-cell function, insulin sensitivity, and glucose biomarkers in two phase 2 trial populations.

Study · 2026

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial

Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor (GLP-1R) dual agonist with the potential to induce greater weight reductions than GLP-1R mono-agonists.

review · 2026

How does survodutide work? Plain language review of a potential new medication for obesity and liver disease

What is this review about? This review provides an overview of a medication called survodutide. Survodutide is not yet approved for use but is currently being tested to treat people living with obesity , as well as those living with MASH (metabolic dysfunction-associated steatohepatitis).

Study · 2026

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

Survodutide is a glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treating obesity and related diseases.

Study · 2026

Survodutide Once Weekly for the Treatment of Adults with Obesity

Background Although medications with glucagon-like peptide-1 (GLP-1) receptor agonist activity have transformed the management of obesity and shown substantial cardiometabolic benefits, unmet needs remain.

Study · 2026

Efficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis

Background Metabolism-associated steatotic liver disease (MASLD) is one of the most prevalent chronic liver diseases worldwide.